ÂÜÀòÉÙÅ®

ESH Translational Research Conferences propose programmes of leading-edge basic and clinical science, as well as opportunities for informal scientific interaction with a panel of global experts in the field. It is open to an international audience of biologists and clinicians, including those still in-training. The presentation of unpublished data is encouraged. Ample time is deliberately provided for in-depth scientific discussion and interaction. Chairs: Jean-Jacques Kiladjian, Ross L. Levine, Ann Mullally, Jyoti Nangalia

New insights into the molecular pathogenesis, classification, and management of patients with Myeloproliferative Neoplasms (MPN) have arisen at increasing pace during the past years. This International Conference brings together scientists and clinicians to present and discuss new data on the cellular and molecular biology of these disorders as well as their diagnosis and treatment.

This conference is accredited by the European Board for Accreditation in Hematology (EBAH) CME system. Participants will be eligible to claim CME credit points.

Posters and Brief Oral Communications:

Registered participants are invited to submit their abstracts. Selected abstracts are eligible for an oral or a poster presentation.

Call for abstracts: Deadline: January 26, 2026

Scientific Topics:

• Somatic evolution and MPN

• New approaches for targeting MPN

• New causes and classification

• Recent developments in blast phase MPN

• Novel functional insights downstream of JAK/CALR/MPL

• MPN management

• Disease mechanisms in MPN

• Aberrant cell populations in MPN

• New frontiers in MPN, where is the field going?

The programme will include:

– Plenary Sessions

– Keynote Lectures

– Panel Discussions

– Simultaneous Meet the Expert Sessions

– Mentored Poster Walks

– Brief Oral Communications

– Ample time for in-depth discussion

The meeting will be of interest to:

• Senior biologists and clinicians, including experts in the field (MD, PhD, MD-PhD)

• Junior scientists and clinicians (MD, PhD)

• PhD candidates and clinical residents still in-training

Learning Objectives:

Upon completion of this CME activity, participants should:

1. To understand the newest discoveries on the molecular pathogenesis of MPN

2. To appreciate recent changes in treatment recommendations for MPN patients including the evolving landscape of

approved therapies

3. To gain insight into ongoing clinical trials investigating novel agents for MPN treatment

Register

Direct email queries to: [email protected]